Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours
Palleon Pharmaceuticals has reported the outcomes from its Phase I/II study of E-602 along with programmed death (PD)-1 inhibitor cemiplimab…
News
Hurricane Helene delays Spectral Medical’s confirmatory trial enrolment
OncoResponse reports data from Phase I solid tumour treatment trial
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
Cofactor’s cancer biomarker test outshines standard ICI predictive tests
Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain
Radella reports positive outcomes from trial of MD-18 for obesity and diabetes
Minister for Science champions partnerships with private clinical sector in UK
